☆ 4.7 Article

The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions

CLINICAL INFECTIOUS DISEASES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial

Ephraim L. Tsalik et al.

Summary: This study aimed to compare the efficacy and safety of azithromycin versus placebo for treating lower respiratory tract infections in patients with low procalcitonin concentrations. The results showed that after 5 days of treatment, azithromycin was not non-inferior to placebo in terms of clinical improvement. However, it is still unclear whether antibiotics are necessary for patients with lower respiratory tract infection and low procalcitonin concentrations.

LANCET INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Immunology

Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs

Tori Kinamon et al.

Summary: A novel DOOR endpoint for complicated intra-abdominal infection (cIAI) was defined and evaluated to understand overall outcomes among trial participants.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Editorial Material Infectious Diseases

Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia

Ahmad Mourad et al.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

添加到收藏夹

Article Immunology

Clinically Adjudicated Reference Standards for Evaluation of Infectious Diseases Diagnostics

Robin Patel et al.

Summary: The lack of a gold standard poses challenges in evaluating the accuracy of diagnostic tests for infectious diseases. Various approaches, such as multitest comparators and clinically adjudicated reference standards, can be used to overcome this challenge.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Immunology

Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials

Jessica Howard-Anderson et al.

Summary: The study applied the DOOR method in three registrational drug trials for complicated urinary tract infections and found no significant difference between the treatment and control groups. DOOR can improve understanding of the trade-offs between clinical efficacy and safety.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Infectious Diseases

Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

Jinnethe Reyes et al.

Summary: This study investigated the characteristics and outcomes of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections and the distribution and clinical significance of carbapenemases. The results showed that carbapenemase-producing CRPA infections were associated with increased 30-day mortality, and the prevalence of carbapenemase genes varied by region. These findings highlight the therapeutic challenges posed by these carbapenem-resistant organisms.

LANCET MICROBE (2023)

添加到收藏夹

Article Immunology

The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations

Scott R. Evans et al.

Summary: Clinical research networks conduct important studies and contribute to scientific advancements by developing new methodologies and tools, addressing common issues, and anticipating future research needs.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Review Microbiology

Considerations for the Use of Phage Therapy in Clinical Practice

Gina A. Suh et al.

Summary: Due to increasing antimicrobial resistance and medical device-related infections, phage therapy has gained renewed interest as an alternative or adjunct to conventional antimicrobials. However, there are significant knowledge gaps in clinical application and laboratory testing of phage therapy, leading to heterogeneity in approach and lack of consensus.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Pediatrics

Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children The SCOUT-CAP Randomized Clinical Trial

Derek J. Williams et al.

Summary: In a study among children with outpatient CAP, a 5-day antibiotic strategy was found to be superior to a 10-day strategy, resulting in similar clinical response and antibiotic-associated adverse effects, while reducing antibiotic exposure and resistance.

JAMA PEDIATRICS (2022)

添加到收藏夹

Article Infectious Diseases

Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study

Minggui Wang et al.

Summary: This study analyzed the bacterial characteristics of CRKP infections and the clinical outcomes of patients with CRKP infections across different countries, revealing significant regional differences in CRKP epidemics.

LANCET INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Nicholas A. Turner et al.

Summary: The DOTS trial aims to compare the efficacy of dalbavancin with standard parenteral antibiotic therapy in treating complicated Staphylococcus aureus bacteremia by evaluating the Desirability of Outcome Ranking (DOOR) at day 70 after treatment.

TRIALS (2022)

添加到收藏夹

Article Microbiology

Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia

M. M. Pettigrew et al.

Summary: This study examined the impact of antibiotic treatment duration on resistance genes and bacteria in the respiratory microbiome. The results showed that a shorter 5-day treatment for pediatric pneumonia led to a significantly lower abundance of antibiotic resistance determinants compared to the standard 10-day treatment.

MBIO (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Genomic characterization of lytic bacteriophages targeting genetically diverse Pseudomonas aeruginosa clinical isolates

Hayley R. Nordstrom et al.

Summary: This study demonstrates how systematic genomic and phenotypic characterization can be deployed to develop bacteriophages as precision antibiotics.

ISCIENCE (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial

Pranita D. Tamma et al.

Summary: This study is a double-blind placebo-controlled trial investigating both the activity of phages in reducing P. aeruginosa colony counts and the safety of phage therapy.

TRIALS (2022)

添加到收藏夹

Article Immunology

Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study

Pranita D. Tamma et al.

Summary: This prospective cohort study investigated the outcomes of patients with ceftriaxone-resistant (CRO-R) Escherichia coli bloodstream infections (BSIs). The study found that patients with CRO-R infections had poorer clinical outcomes compared to those with ceftriaxone-susceptible (CRO-S) infections. The analysis revealed that the CRO-R group had a higher proportion of Pitt bacteremia score >= 4 and a longer time to receive active antibiotic therapy. However, after adjusting for confounding factors using inverse probability weighting, there was no significant difference in the desired outcomes between the two groups. Secondary outcomes showed higher 30-day mortality, longer length of stay, and increased incidence of admission to long-term care facilities in the CRO-R group.

OPEN FORUM INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Microbiology

Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults

Thomas P. Lodise et al.

Summary: This study described the pharmacokinetic (PK) characteristics of ceftazidime-avibactam (CZA) and aztreonam (ATM) in combination and assessed the association between ATM exposure and alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations. The study found that CZA-ATM administration reduced ATM clearance and did not exacerbate AST/ALT elevations. Continuous infusion of ATM should be used with caution.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Microbiology

Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers

Thomas P. Lodise et al.

Summary: This study evaluated the safety of the optimal ceftazidime-avibactam (CZA) with aztreonam (ATM) regimens identified in infection models of MBL-producing Enterobacterales. The results suggest that CZA-ATM administered as 2-h intermittent infusions is safe and caution should be exercised with the use of ATM continuous infusion at a high dose.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Immunology

REPORTing of Antimicrobial Resistance from Blood Cultures (REPORT-ABC), an ARLG Survey Summary: Resistance Marker Reporting Practices from Positive Blood Cultures

Patricia J. Simner et al.

Summary: Approaches to reporting molecular antibacterial resistance test results from positive blood culture broths vary significantly across clinical laboratories. Providing interpretive comments with therapeutic guidance alongside results reported may assist clinicians who are not well-versed in genetic mechanisms of AMR. However, this is currently not being done in all clinical laboratories. Standardized strategies for AMR gene result reporting are needed.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Immunology

Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram-negative Bacteremia: RAPIDS-GN

Ritu Banerjee et al.

Summary: The study demonstrated that rapid organism identification and phenotypic AST can lead to faster antibiotic therapy adjustments for patients with gram-negative bloodstream infections (BSIs), ultimately improving treatment outcomes.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pranita D. Tamma et al.

Summary: This guidance document provides recommendations for the treatment of antimicrobial-resistant infections commonly encountered in US hospitals, focusing on ESBL-E, CRE, and DTR-P. aeruginosa. It includes preferred and alternative treatment recommendations, discussion on empiric treatment selection and management considerations, and will be periodically updated. The current version is as of 17 September 2020, with plans to expand recommendations to include other problematic gram-negative pathogens in future versions.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Critical Care Medicine

Discriminating Bacterial and Viral Infection Using a Rapid Host Gene Expression Test

Ephraim L. Tsalik et al.

Summary: This study described and validated a host response bacterial/viral test using an independent patient cohort, showing its good performance in discriminating bacterial and viral infections, compared to procalcitonin. The test provided rapid and accurate discrimination of bacterial and viral infections, supporting more appropriate antibiotic use.

CRITICAL CARE MEDICINE (2021)

添加到收藏夹

Article Microbiology

Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically III Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)

Thomas P. Lodise et al.

Summary: This multicenter study investigated the pharmacokinetics and pharmacokinetic-pharmacodynamic profile of intravenous minocycline in critically ill patients with MDR Acinetobacter baumannii infections. The study found that the dosing regimen of minocycline 200 mg i.v. every 12 hours may not be optimal for patients with MIC values of >1 mg/liter, requiring further clinical confirmation.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Immunology

Average Weighted Accuracy: Pragmatic Analysis for a Rapid Diagnostics in Categorizing Acute Lung Infections (RADICAL) Study

Ying Liu et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Immunology

The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)

Thomas P. Lodise et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Infectious Diseases

Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study

David van Duin et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Therapeutic monitoring of vancomycin for serious -methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists

Michael J. Rybak et al.

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2020)

添加到收藏夹

Article Infectious Diseases

Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model

Thomas P. Lodise et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

添加到收藏夹

Article Medicine, General & Internal

Multidrug-Resistant Bacterial Infections in US Hospitalized Patients, 2012-2017

John A. Jernigan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants (PROOF)

E Wenzler et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

添加到收藏夹

Article Immunology

Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

David van Duin et al.

CLINICAL INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Immunology

MASTERMIND: Bringing Microbial Diagnostics to the Clinic

Robin Patel et al.

CLINICAL INFECTIOUS DISEASES (2017)

添加到收藏夹

Article Microbiology

Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Steven Marshall et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

添加到收藏夹

Article Immunology

Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME)

Scott R. Evans et al.

CLINICAL INFECTIOUS DISEASES (2016)

添加到收藏夹

Article Cell Biology

Host gene expression classifiers diagnose acute respiratory illness etiology

Ephraim L. Tsalik et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

添加到收藏夹

Article Immunology

Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing

Ritu Banerjee et al.

CLINICAL INFECTIOUS DISEASES (2015)

添加到收藏夹

Article Microbiology

Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network

David van Duin et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.